Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT05427058 Not yet recruiting - Cervical Cancer Clinical Trials

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study compared the efficacy and safety of superior hypogastric plexus block and ganglion impar block procedures on the management of pelvic and perineal cancer pain in patients with cervical and endometrial cancer

NCT ID: NCT05426642 Not yet recruiting - Clinical trials for Cervical Cancer Screening

The Effect of E-health Video Towards Enhancing Cervical Cancer Screening

Start date: March 2023
Phase: N/A
Study type: Interventional

The aim of this quasi-experimental study is to evaluate the women's motivation related to cervical cancer screening. The experiment group will receive the e-health video KaSEH and brochure as the intervention. Where as, the control group will receive brochure as the intervention. There is three phase of evaluation which are pre-intervention, intra-intervention and post-intervention. The evaluation will be assess using the self-administered questionnaire based on Protection Motivation Theory. The estimated duration of this quasi-experiment is six month.

NCT ID: NCT05421650 Recruiting - Cervical Cancer Clinical Trials

Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study is a prospective, multicenter and randomized clinical trial (DEBULK trial) to determine the therapeutic effect of surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT) in cervical cancer stage IIICr.

NCT ID: NCT05420545 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05414097 Completed - Cervical Cancer Clinical Trials

Finding Barriers and Designing Solutions to Promote Women s Cancer Screening in South Africa

FIND
Start date: July 16, 2022
Phase:
Study type: Observational

The primary aim of the study explore drivers of cervical cancer screening and barriers contributing to low screening coverage among women in South Africa. Secondary aims are determining preferences for cervical cancer prevention services using a discrete choice experiment and developing a multi-level package of interventions that will address barriers to cervical cancer screening and improve engagement in care among women.

NCT ID: NCT05413798 Recruiting - Cervical Cancer Clinical Trials

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Start date: May 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.

NCT ID: NCT05410444 Completed - Clinical trials for Uterine Cervical Neoplasms

The Role of Clean Intermittent Catheterization in Patients Undergoing Radiotherapy After Radical Hysterectomy for Cervical Cancer

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Through a prospective, randomized and controlled research design method, this study implemented intermittent catheterization for patients with urinary dysfunction after postoperative radiotherapy of cervical cancer, formulated a reasonable bladder rehabilitation training plan, reduced the amount of residual urine, restored bladder function as soon as possible, reduced the incidence of urinary complications and readmission rate, and improved the quality of life of patients, To comprehensively evaluate the application value of intermittent catheterization in patients with micturition dysfunction after postoperative radiotherapy for cervical cancer.

NCT ID: NCT05406856 Recruiting - Clinical trials for Uterine Cervical Neoplasms

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

PROTECT
Start date: May 2, 2022
Phase: N/A
Study type: Interventional

This prospective, multicenter, nonrandomized phase-II-trial investigates in clinical practice the differences between intensity modulated proton therapy (IMPT) and standard intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) in the effects on dose-volume parameters and treatment-related morbidity for women with locally advanced cervical cancer undergoing chemoradiation.

NCT ID: NCT05401175 Recruiting - Cervical Cancer Clinical Trials

Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer

Start date: April 13, 2022
Phase: N/A
Study type: Interventional

The aim of this project is to promote the reconstruction of haematopoietic function after chemoradiotherapy for cervical cancer with the innovative use of autologous haematopoietic containing stem cell blood transfusion support.To explore the effect of stored hemopoietic stem cell support therapy on bone marrow protection after concurrent chemoradiotherapy, in order to promote its clinical application.

NCT ID: NCT05393635 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

ITIL-168 in Advanced Solid Tumors

DELTA-2
Start date: August 2022
Phase: Phase 1
Study type: Interventional

DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).